Invetx

Invetx is a biopharma startup that aims to revolutionize animal health by leveraging biotechnology. Founded in 2018 and headquartered in the United States, the company has garnered significant attention through its recent $60.50M Series B investment on 10 May 2022. Notable investors in this round include Novo Holdings, Casdin Capital, Eight Roads Ventures, F-Prime Capital, GV, Anterra Capital, and Tekla Capital. Invetx's mission is to channel the advancements in biopharma into animal health, positioning itself as the premier animal health biotechnology innovation platform for protein-based therapeutics. Collaborating with leading biotechnology companies and a vast network of industry experts, the company is dedicated to curating a diverse portfolio of therapies and technologies to reshape the future of animal care. By uniting professionals in both animal and human health, including veterinary scientists and clinicians, Invetx aspires to optimize biopharma technologies for the betterment of pets and farm animal populations. With a strong online presence, the company can also be followed on Twitter at @Invetx. Invetx's vision foresees the global animal health industry harnessing biopharma technologies to deliver considerable advancements in health outcomes for animals. This strategic focus on bridging biopharma and animal health sets Invetx on a promising trajectory within the biopharma and biotechnology industries.